New developments in the treatment of schizophrenia.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Psychiatry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 17388719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

  2006cited by this paper
• The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials

  2006cited by this paper
• Drug initiatives to improve cognitive function.

  2006cited by this paper
• Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits

  2006cited by this paper
• Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

  2006cited by this paper
• Cognitive Development in Schizophrenia: Follow-Back from the First Episode

  2006cited by this paper
• Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

  2006cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Clinical implications of Brief Psychiatric Rating Scale scores.

  2005cited by this paper
• Biosocial pathways to functional outcome in schizophrenia.

  2005cited by this paper
• What does the PANSS mean?

  2005cited by this paper
• Efficacy of antidepressants in adults

  2005cited by this paper
• Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.

  2005cited by this paper
• A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

  2005cited by this paper
• Premorbid neurocognitive functioning in schizophrenia spectrum disorder.

  2005cited by this paper
• Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

  2004cited by this paper
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

  2004cited by this paper
• Schizophrenia and employment

  2004cited by this paper
• Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients

  2004cited by this paper
• Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

  2004cited by this paper
• Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

  2004cited by this paper
• Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

  2004cited by this paper
• Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

  2004cited by this paper
• Long-Acting Risperidone

  2004cited by this paper
• Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

  2004cited by this paper
• Patient Attitudes towards Surgically Implantable, Long-Term Delivery of Psychiatric Medicine

  2004cited by this paper
• Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

  2004cited by this paper
• Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.

  2003cited by this paper
• Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine

  2003cited by this paper
• A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.

  2003cited by this paper
• An economic review of compliance with medication therapy in the treatment of schizophrenia.

  2003cited by this paper
• The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

  2003cited by this paper
• Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

  2003cited by this paper
• Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone

  2003cited by this paper
• Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

  2003cited by this paper
• A meta-analysis of the efficacy of second-generation antipsychotics.

  2003cited by this paper
• Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia

  2003cited by this paper
• Predictors of noncompliance in patients with schizophrenia.

  2002cited by this paper
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].

  2002cited by this paper
• Surgically Implantable Long-term Antipsychotic Delivery Systems for the Treatment of Schizophrenia

  2002cited by this paper
• Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

  2002cited by this paper
• Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

  2001cited by this paper
• Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.

  2000cited by this paper
• Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

  2000cited by this paper
• Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects.

  1999cited by this paper
• Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.

  1999cited by this paper
• Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.

  1998cited by this paper
• Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

  1998cited by this paper
• Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

  1998cited by this paper
• Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

  1998cited by this paper
• A qualitative study of medication-taking behaviour in primary care.

  1997cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms

  1997cited by this paper
• Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

  1996cited by this paper
• Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry.

  1996cited by this paper
• What are the functional consequences of neurocognitive deficits in schizophrenia?

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders.

  1995cited by this paper
• Clozapine in tardive dyskinesia: observations from human and animal model studies.

  1994cited by this paper
• Risperidone in the treatment of schizophrenia.

  1994cited by this paper
• Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research.

  1992cited by this paper
• Neuropsychological assessment of monozygotic twins discordant for schizophrenia.

  1990cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Course types in schizophrenia: an analysis of European and American studies.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later.

  1987cited by this paper
• Polylactic acid for surgical implants

  1966cited by this paper

• Characterization of a novel antibiotic isolated from Xenorhabdus khoisanae and encapsulation of vancomycin in nanoparticles

  2018cites this paper